title: Novel routes for allergen immunotherapy: safety, efficacy and mode of action.
abstract: Allergen immunotherapy is the only curative treatment of IgE-mediated type I respiratory allergies. Subcutaneous immunotherapy (SCIT) is used as a reference therapy and has transformed allergic treatments; it improves symptoms (asthma and rhinitis) as well as the quality of life of patients. SCIT requires repetitive administration and carries the risk of severe systemic adverse effects, including anaphylaxis. Sublingual immunotherapy is now a valid noninvasive alternative to SCIT, as a safe and efficacious treatment for respiratory allergies. In this article, we compare various routes of allergen immunotherapy, including SCIT and sublingual immunotherapy, as well as more exploratory routes currently under investigation (i.e., intralymphatic, epicutaneous, intranasal and oral). We discuss their respective advantages, as well as their foreseen modes of action.
authors.affiliation: Stallergenes SA, Département Scientifique, 6 rue Alexis de Tocqueville, 92160 Antony, France.
authors.forename: Philippe
authors.initials: P
authors.lastname: Moingeon
authors.forename: Laurent
authors.initials: L
authors.lastname: Mascarell
mesh_terms: D000485:Allergens / Q000627:therapeutic use; D000707:Anaphylaxis / Q000209:etiology / Q000517:prevention & control; D000818:Animals; D003888:Desensitization, Immunologic / Q000009:adverse effects / Q000379:methods* / Q000639:trends; D004333:Drug Administration Routes; D006801:Humans; D006967:Hypersensitivity / Q000150:complications / Q000276:immunology* / Q000628:therapy*; D011788:Quality of Life; D016896:Treatment Outcome
chemical_list: D000485:Allergens